Mosanna Therapeutics | 1,348 followers on LinkedIn. Mosanna is a clinical-stage company pioneering a novel pharmaceutical approach to treat obstructive sleep apnea (OSA). | Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF).